The Vanguard Group 13D and 13G filings for Viking Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-12 5:54 pm Unchanged |
2024-09-30 | 13G | Viking Therapeutics, Inc. VKTX |
The Vanguard Group | 10,167,614 9.170% |
0 (Unchanged) |
Filing |
| 2024-11-04 1:54 pm Purchase |
2024-09-30 | 13G | Viking Therapeutics, Inc. VKTX |
The Vanguard Group | 10,167,614 9.170% |
4,785,710 (+88.92%) |
Filing |
| 2024-02-13 5:17 pm Purchase |
2023-12-29 | 13G | Viking Therapeutics, Inc. VKTX |
The Vanguard Group | 5,381,904 5.380% |
5,381,904 (New Position) |
Filing |